Status:
COMPLETED
Effect of Biphasic Insulin Aspart 30 Combined With Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This trial is conducted in Asia. This single arm trial aims to evaluate the blood glucose control with twice daily biphasic insulin aspart 30 in combination with metformin in Chinese subjects with typ...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Currently treated with basal insulin once or twice daily with or without oral anti-diabetic drugs (OADs) for at least 3 months
- HbA1c (glycosylated haemoglobin A1c) within the range of 7.5% to10.0% ( both inclusive)
- BMI (Body Mass Index) maximum 40 kg/m2
Exclusion
- Metformin contraindications according to local practice
- Systemically treated with TZDs (thiazolidinediones) for more than one month within 6 months prior to this trial
Key Trial Info
Start Date :
November 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
293 Patients enrolled
Trial Details
Trial ID
NCT00669864
Start Date
November 1 2007
End Date
April 1 2009
Last Update
April 1 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, Beijing Municipality, China, 100034